KURN Share Price Performance
CHF 0
-20.20 (-100.00%)
Price CHF 0
Fair ValueCHF 32.80
Share Pricen/a
Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts
Oct 18
Kuros Biosciences AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
KURN Community Narratives
AN
Fair Value CHF 32.8 15.5% undervalued intrinsic discount
Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity
Catalysts About Kuros Biosciences Kuros Biosciences develops and commercializes advanced synthetic bone graft technologies for spine and extremity surgery, supported by high-quality clinical evidence. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
CHF 32.8
15.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
38.58% p.a.
Profit Margin
13%
Future PE
49.82x
Price in 2028
CHF 36.83
Trending Discussion
Recently Updated Narratives
AN
Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity
Fair Value: CHF 32.8 15.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kuros Biosciences AG Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Mar 10, 2026
- -0.15
- 88.70%
- -5.71%
- 0%
About KURN
- Founded
- 2016
- Employees
- 158
- CEO
- WebsiteView website
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
